Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment

Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, briefly discusses the Phase II GMMG-DANTE trial (NCT02977494), which investigated the combination of daratumumab, bortezomib and dexamethasone (DVd) in patients with multiple myeloma and renal impairment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene
Research support: AbbVie, GSK (both to the institution)
Travel support: Sanofi
Other (travel support, training): GSK, Sanofi, AbbVie